Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 1
1966 1
1967 1
1968 1
1969 2
1970 4
1971 3
1972 5
1973 5
1974 3
1975 5
1976 6
1977 5
1978 6
1979 9
1980 7
1981 4
1982 13
1983 5
1984 6
1985 10
1986 17
1987 19
1988 21
1989 27
1990 31
1991 32
1992 41
1993 52
1994 59
1995 56
1996 45
1997 48
1998 85
1999 92
2000 86
2001 113
2002 97
2003 89
2004 93
2005 85
2006 132
2007 100
2008 81
2009 77
2010 75
2011 64
2012 74
2013 71
2014 69
2015 56
2016 74
2017 90
2018 77
2019 94
2020 108
2021 121
2022 47
Text availability
Article attribute
Article type
Publication date

Search Results

2,522 results
Results by year
Filters applied: . Clear all
Page 1
Drp1 Tubulates the ER in a GTPase-Independent Manner.
Adachi Y, Kato T, Yamada T, Murata D, Arai K, Stahelin RV, Chan DC, Iijima M, Sesaki H. Adachi Y, et al. Mol Cell. 2020 Nov 19;80(4):621-632.e6. doi: 10.1016/j.molcel.2020.10.013. Epub 2020 Nov 4. Mol Cell. 2020. PMID: 33152269 Free PMC article.
Mitochondrial Stasis Reveals p62-Mediated Ubiquitination in Parkin-Independent Mitophagy and Mitigates Nonalcoholic Fatty Liver Disease.
Yamada T, Murata D, Adachi Y, Itoh K, Kameoka S, Igarashi A, Kato T, Araki Y, Huganir RL, Dawson TM, Yanagawa T, Okamoto K, Iijima M, Sesaki H. Yamada T, et al. Among authors: adachi y. Cell Metab. 2018 Oct 2;28(4):588-604.e5. doi: 10.1016/j.cmet.2018.06.014. Epub 2018 Jul 12. Cell Metab. 2018. PMID: 30017357 Free PMC article.
A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses.
Steichen JM, Lin YC, Havenar-Daughton C, Pecetta S, Ozorowski G, Willis JR, Toy L, Sok D, Liguori A, Kratochvil S, Torres JL, Kalyuzhniy O, Melzi E, Kulp DW, Raemisch S, Hu X, Bernard SM, Georgeson E, Phelps N, Adachi Y, Kubitz M, Landais E, Umotoy J, Robinson A, Briney B, Wilson IA, Burton DR, Ward AB, Crotty S, Batista FD, Schief WR. Steichen JM, et al. Among authors: adachi y. Science. 2019 Dec 6;366(6470):eaax4380. doi: 10.1126/science.aax4380. Epub 2019 Oct 31. Science. 2019. PMID: 31672916 Free PMC article.
Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
Moriyama S, Adachi Y, Sato T, Tonouchi K, Sun L, Fukushi S, Yamada S, Kinoshita H, Nojima K, Kanno T, Tobiume M, Ishijima K, Kuroda Y, Park ES, Onodera T, Matsumura T, Takano T, Terahara K, Isogawa M, Nishiyama A, Kawana-Tachikawa A, Shinkai M, Tachikawa N, Nakamura S, Okai T, Okuma K, Matano T, Fujimoto T, Maeda K, Ohnishi M, Wakita T, Suzuki T, Takahashi Y. Moriyama S, et al. Among authors: adachi y. Immunity. 2021 Aug 10;54(8):1841-1852.e4. doi: 10.1016/j.immuni.2021.06.015. Epub 2021 Jul 2. Immunity. 2021. PMID: 34246326 Free PMC article.
HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen.
Jardine JG, Kulp DW, Havenar-Daughton C, Sarkar A, Briney B, Sok D, Sesterhenn F, Ereño-Orbea J, Kalyuzhniy O, Deresa I, Hu X, Spencer S, Jones M, Georgeson E, Adachi Y, Kubitz M, deCamp AC, Julien JP, Wilson IA, Burton DR, Crotty S, Schief WR. Jardine JG, et al. Among authors: adachi y. Science. 2016 Mar 25;351(6280):1458-63. doi: 10.1126/science.aad9195. Science. 2016. PMID: 27013733 Free PMC article.
A SARS-CoV-2 antibody broadly neutralizes SARS-related coronaviruses and variants by coordinated recognition of a virus-vulnerable site.
Onodera T, Kita S, Adachi Y, Moriyama S, Sato A, Nomura T, Sakakibara S, Inoue T, Tadokoro T, Anraku Y, Yumoto K, Tian C, Fukuhara H, Sasaki M, Orba Y, Shiwa N, Iwata N, Nagata N, Suzuki T, Sasaki J, Sekizuka T, Tonouchi K, Sun L, Fukushi S, Satofuka H, Kazuki Y, Oshimura M, Kurosaki T, Kuroda M, Matsuura Y, Suzuki T, Sawa H, Hashiguchi T, Maenaka K, Takahashi Y. Onodera T, et al. Among authors: adachi y. Immunity. 2021 Oct 12;54(10):2385-2398.e10. doi: 10.1016/j.immuni.2021.08.025. Epub 2021 Aug 24. Immunity. 2021. PMID: 34508662 Free PMC article.
High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab.
Lee CH, DiNatale RG, Chowell D, Krishna C, Makarov V, Valero C, Vuong L, Lee M, Weiss K, Hoen D, Morris L, Reznik E, Murray S, Kotecha R, Voss MH, Carlo MI, Feldman D, Sachdev P, Adachi Y, Minoshima Y, Matsui J, Funahashi Y, Nomoto K, Hakimi AA, Motzer RJ, Chan TA. Lee CH, et al. Among authors: adachi y. Mol Cancer Res. 2021 Sep;19(9):1510-1521. doi: 10.1158/1541-7786.MCR-21-0053. Epub 2021 May 26. Mol Cancer Res. 2021. PMID: 34039647 Free PMC article. Clinical Trial.
A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.
Yamaura T, Nakatani T, Uda K, Ogura H, Shin W, Kurokawa N, Saito K, Fujikawa N, Date T, Takasaki M, Terada D, Hirai A, Akashi A, Chen F, Adachi Y, Ishikawa Y, Hayakawa F, Hagiwara S, Naoe T, Kiyoi H. Yamaura T, et al. Among authors: adachi y. Blood. 2018 Jan 25;131(4):426-438. doi: 10.1182/blood-2017-05-786657. Epub 2017 Nov 29. Blood. 2018. PMID: 29187377 Free article.
2,522 results